Laboratory Developed Tests: FAQs
On these pages you’ll find answers to the most common questions FDA has received through ldtfinalrule@fda.hhs.gov related to laboratory developed tests (LDTs). To ensure we are answering generally applicable questions in a manner that is transparent, we intend to respond to questions submitted to the mailbox, as appropriate, in a public manner, such as in webinars, guidances, this FAQ page, and other resources over the course of the phaseout period. FDA intends to update this FAQ page periodically. If you cannot find the answer you’re looking for, please contact FDA through the mailbox at ldtfinalrule@fda.hhs.gov.
- Definitions and General Oversight
- Phaseout Policy and Enforcement Discretion Policies
- MDRs, Complaints, and Corrections & Removals Reporting
- Labeling
- Premarket Review
- Investigational Use
- Specific Test Categories or Technologies
- Resources and Interactions with FDA